全文获取类型
收费全文 | 5138篇 |
免费 | 329篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 165篇 |
妇产科学 | 96篇 |
基础医学 | 676篇 |
口腔科学 | 34篇 |
临床医学 | 660篇 |
内科学 | 925篇 |
皮肤病学 | 102篇 |
神经病学 | 497篇 |
特种医学 | 145篇 |
外科学 | 953篇 |
综合类 | 94篇 |
一般理论 | 2篇 |
预防医学 | 484篇 |
眼科学 | 63篇 |
药学 | 284篇 |
中国医学 | 4篇 |
肿瘤学 | 235篇 |
出版年
2023年 | 26篇 |
2022年 | 60篇 |
2021年 | 142篇 |
2020年 | 69篇 |
2019年 | 113篇 |
2018年 | 170篇 |
2017年 | 100篇 |
2016年 | 106篇 |
2015年 | 135篇 |
2014年 | 166篇 |
2013年 | 239篇 |
2012年 | 389篇 |
2011年 | 407篇 |
2010年 | 231篇 |
2009年 | 185篇 |
2008年 | 366篇 |
2007年 | 328篇 |
2006年 | 304篇 |
2005年 | 283篇 |
2004年 | 299篇 |
2003年 | 251篇 |
2002年 | 228篇 |
2001年 | 60篇 |
2000年 | 52篇 |
1999年 | 51篇 |
1998年 | 35篇 |
1997年 | 27篇 |
1996年 | 26篇 |
1995年 | 23篇 |
1992年 | 40篇 |
1991年 | 29篇 |
1990年 | 42篇 |
1989年 | 37篇 |
1988年 | 30篇 |
1987年 | 42篇 |
1986年 | 51篇 |
1985年 | 37篇 |
1984年 | 30篇 |
1983年 | 14篇 |
1981年 | 12篇 |
1980年 | 16篇 |
1979年 | 26篇 |
1978年 | 14篇 |
1977年 | 13篇 |
1975年 | 14篇 |
1974年 | 12篇 |
1973年 | 17篇 |
1972年 | 14篇 |
1971年 | 13篇 |
1970年 | 14篇 |
排序方式: 共有5480条查询结果,搜索用时 15 毫秒
111.
Increased fibrinolysis and amyloidosis 总被引:2,自引:0,他引:2
H Liebman M Chinowsky J Valdin G Kenoyer D Feinstein 《Archives of internal medicine》1983,143(4):678-682
We studied three patients with amyloidosis who had a significant hemorrhagic disorder secondary to increased fibrinolysis. In two of the three patients, bleeding was one of the major initial problems; in the other patient, bleeding occurred later in the course of the disease. All three patients were men with primary or myeloma-associated amyloidosis (ie, immunoglobulin-related or AL). None of the patients had significantly impaired liver function at the time of the diagnosis of increased fibrinolysis. At admission, fibrinogen levels were 60, 170, and 90 mg/dL in the three patients. All three patients had short euglobulin clot lysis times (less than 30 minutes) and evidence of in vitro clot lysis. One patient appeared to respond to aminocaproic acid (EACA). In patients with amyloidosis and bleeding, fibrinolytic tests should be done; in patients with increased fibrinolysis, a diagnosis of amyloidosis should be considered. 相似文献
112.
Plasmin inhibition of thrombin-induced platelet aggregation. 总被引:7,自引:0,他引:7
The effects of plasmin treatment upon washed human platelets were studied in an attempt to elucidate the mechanisms underlying thrombin-induced platelet aggregation. At calcium concentrations of 10-20 muM, PLASMIN (0.2 CTA U/ml) inhibited thrombin-induced aggregation almost completely, but did not diminish the thrombin-induced release of adenine nucleotides, 5-hydroxytryptamine, or calcium. Increasing the calcium concentration partially antagonized plasmin's inhibition of aggregation. Studies utilizing calcium chelators and the Kunitz soybean trypsin inhibitor (SBTI) as a plasmin inhibitor indicated that in order to achieve maximal block of aggregation, plasmin must act upon a substrate made fully available only after an initial thrombin-platelet interaction has taken place. Moreover, the time course of this inhibition parallels the time course of the thrombin-induced release reaction. Plasmin inhibition of aggregation could not be mimicked by exposing the platelets to proteolytic digests of fibrinogen at concentrations as high as 17% total platelet protein. Nor could inhibitory activity be recovered from supernatants of plasmin-treated platelets, upon centrifugation and treatment with SBTI. With the use of a "cold initiation" technique, the release by thrombin of 46.7 plus or minus 6.7 (mean plus or minus SEM) mu-g of fibrinogen immunological equivalents per mg platelet protein could be demonstrated. Platelets in which thrombin-induced aggregation was abolished by plasmin treatment (and the plasmin subsequently inactivated by STBI) aggregated normally upon addition of as little as 10 mu-g human plasma fibrinogen per mg platelet protein. It is concluded that plasmin inhibition of aggregation most likely results from its attack upon a protein that is released or becomes fully available subsequent to interaction of thrombin with a platelet receptor mediating release. The results of this study are consistent with a cofactor role for fibrinogen in the aggregation of human platelets by thrombin. 相似文献
113.
Patrick J. Cimino Yue Yang Xianwu Li Jake F. Hemingway Makenzie K. Cherne Shawn B. Khademi Yoshinori Fukui Kathleen S. Montine Thomas J. Montine C. Dirk Keene 《Experimental and molecular pathology》2013
Alzheimer's disease (AD) neuropathology is characterized by innate immune activation primarily through prostaglandin E2 (PGE2) signaling. Dedicator of cytokinesis 2 (DOCK2) is a guanyl nucleotide exchange factor expressed exclusively in microglia in the brain and is regulated by PGE2 receptor EP2. DOCK2 modulates microglia cytokine secretion, phagocytosis, and paracrine neurotoxicity. EP2 ablation in experimental AD results in reduced oxidative damage and amyloid beta (Aβ) burden. This discovery led us to hypothesize that genetic ablation of DOCK2 would replicate the anti-Aβ effects of loss of EP2 in experimental AD. To test this hypothesis, we crossed mice that lacked DOCK2 (DOCK2 −/−), were hemizygous for DOCK2 (DOCK2 +/−), or that expressed two DOCK2 genes (DOCK2 +/+) with APPswe-PS1Δe9 mice (a model of AD). While we found no DOCK2-dependent differences in cortex or in hippocampal microglia density or morphology in APPswe-PS1Δe9 mice, cerebral cortical and hippocampal Aβ plaque area and size were significantly reduced in 10-month-old APPswe-PS1Δe9/DOCK2 −/− mice compared with APPswe-PS1Δe9/DOCK2 +/+ controls. DOCK2 hemizygous APPswe-PS1Δe9 mice had intermediate Aβ plaque levels. Interestingly, soluble Aβ42 was not significantly different among the three genotypes, suggesting the effects were mediated specifically in fibrillar Aβ. In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD. 相似文献
114.
Michael A. Pfaller Shawn A. Messer Leah N. Woosley Ronald N. Jones Mariana Castanheira 《Journal of clinical microbiology》2013,51(8):2571-2581
The SENTRY Antimicrobial Surveillance Program monitors global susceptibility and resistance rates of newer and established antifungal agents. We report the echinocandin and triazole antifungal susceptibility patterns for 3,418 contemporary clinical isolates of yeasts and molds. The isolates were obtained from 98 laboratories in 34 countries during 2010 and 2011. Yeasts not presumptively identified by CHROMagar, the trehalose test, or growth at 42°C and all molds were sequence identified using internal transcribed spacer (ITS) and 28S (yeasts) or ITS, translation elongation factor (TEF), and 28S (molds) genes. Susceptibility testing was performed against 7 antifungals (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods. Rates of resistance to all agents were determined using the new CLSI clinical breakpoints and epidemiological cutoff value criteria, as appropriate. Sequencing of fks hot spots was performed for echinocandin non-wild-type (WT) strains. Isolates included 3,107 from 21 Candida spp., 146 from 9 Aspergillus spp., 84 from Cryptococcus neoformans, 40 from 23 other mold species, and 41 from 9 other yeast species. Among Candida spp., resistance to the echinocandins was low (0.0 to 1.7%). Candida albicans and Candida glabrata that were resistant to anidulafungin, caspofungin, or micafungin were shown to have fks mutations. Resistance to fluconazole was low among the isolates of C. albicans (0.4%), Candida tropicalis (1.3%), and Candida parapsilosis (2.1%); however, 8.8% of C. glabrata isolates were resistant to fluconazole. Among echinocandin-resistant C. glabrata isolates from 2011, 38% were fluconazole resistant. Voriconazole was active against all Candida spp. except C. glabrata (10.5% non-WT), whereas posaconazole showed decreased activity against C. albicans (4.4%) and Candida krusei (15.2% non-WT). All agents except for the echinocandins were active against C. neoformans, and the triazoles were active against other yeasts (MIC90, 2 μg/ml). The echinocandins and triazoles were active against Aspergillus spp. (MIC90/minimum effective concentration [MEC90] range, 0.015 to 2 μg/ml), but the echinocandins were not active against other molds (MEC90 range, 4 to >16 μg/ml). Overall, echinocandin and triazole resistance rates were low; however, the fluconazole and echinocandin coresistance among C. glabrata strains warrants continued close surveillance. 相似文献
115.
116.
Chiaravalloti Nancy D. Amato Maria Pia Brichetto Giampaolo Chataway Jeremy Dalgas Ulrik DeLuca John Meza Cecilia Moore Nancy B. Feys Peter Filippi Massimo Freeman Jennifer Inglese Matilde Motl Rob Rocca Maria Assunta Sandroff Brian M. Salter Amber Cutter Gary Feinstein Anthony 《Journal of neurology》2021,268(5):1598-1607
Journal of Neurology - Individuals with pre-existing chronic illness have shown increased anxiety and depression due to COVID-19. Here, we examine the impact of the COVID-19 pandemic on emotional... 相似文献
117.
118.
Nicolas K Khattar Andrew C White Aurora S Cruz Shawn W Adams Kimberly S Meyer Haring JW Nauta Dale Ding Robert F James 《Interventional neuroradiology》2021,27(3):388
Ruptured vertebrobasilar dissecting aneurysms require urgent, often challenging treatment as they have with a high re-hemorrhage rate within the first 24 hours. The patient is a 57-year-old woman who presented with severe-sudden onset headache. Further work up showed a ruptured dissecting aneurysm of the caudal loop of the posterior inferior cerebellar artery (PICA) with associated narrowing distally, in the ascending limb. The aneurysm was immediately occluded with a Woven Endobridge (WEB) device (MicroVention, Tustin, CA, USA) while flow diversion treatment of the diseased ascending limb was postponed. Follow-up angiography three months later showed complete occlusion of the aneurysm, as well as healing of the diseased distal vessel, obviating the need for further intervention. WEB embolization of a ruptured dissecting posterior circulation aneurysm provided an excellent outcome for this patient. 相似文献
119.
Multi‐echo gradient recalled echo imaging of the pelvis for improved depiction of brachytherapy seeds and fiducial markers facilitating radiotherapy planning and treatment of prostatic carcinoma 下载免费PDF全文
120.
Howard Vernon Rocco Guerriero Shawn Kavanaugh Aaron Puhl 《The Journal of the Canadian Chiropractic Association》2015,59(3):288-293
Objectives:Modify the Tampa Scale for Kinesiophobia (TSK) for ‘fear of passive motion’ beliefs.Methods:With permission, a 14-item modification, the TSK-PM (passive movement), was created. Test-retest reliability was tested first. Construct validity was tested in chronic whiplash patients by comparing the TSK-PM with the TSK, the Neck Disability Index (NDI) and cervical ranges of motion.Results:The TSK-PM showed high test-retest reliability (r = 0.83) and high correlation with the original TSK (r = 0.84). Low, non-significant correlations were found with other variables. NDI scores were strongly correlated with ranges of motion.Conclusions:While having high test-retest reliability and a single factor structure, the TSK-PM failed to demonstrate distinctive construct validity vs the original TSK. The original TSK is likely to be sufficient to assess fear of being moved in neck pain patients in a clinical setting. Modifications to the current version of the TSK-PM might improve its construct validity in future studies. 相似文献